Chylomicronemia From GPIHBP1 Autoantibodies Successfully Treated With Rituximab: A Case Report

Ann Intern Med. 2020 Nov 3;173(9):764-765. doi: 10.7326/L20-0327. Epub 2020 Aug 11.

Affiliations

¹ Central Rhine Hospital Group, Koblenz, Germany (J.L., M.D., S.A.).
² Charité University Medicine Campus Virchow, Berlin, Germany (U.K.).
³ Gunma University Graduate School of Medicine, Maebashi, Japan (K.M., M.M., K.N.).
⁴ Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark (M.P.).
⁵ University of California, Los Angeles, Los Angeles, California (L.G.F., S.G.Y., A.P.B.).

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Autoantibodies / blood*
Female
Humans
Hyperlipoproteinemia Type I / diagnosis
Hyperlipoproteinemia Type I / drug therapy*
Hyperlipoproteinemia Type I / immunology*
Immunologic Factors / therapeutic use*
Receptors, Lipoprotein / immunology*
Rituximab / therapeutic use*

Substances

Autoantibodies
GPIHBP1 protein, human
Immunologic Factors
Receptors, Lipoprotein
Rituximab

Grants and funding